Adaptimmune

  • Home
  • Our Company
    • Overview arrow_forward
    • Board of Directors arrow_forward
    • Leadership Team arrow_forward
  • Products
  • Pipeline
    • Overview arrow_forward
    • Afami-cel arrow_forward
    • Lete-cel arrow_forward
    • Uza-cel arrow_forward
  • Technology
    • Overview arrow_forward
    • Manufacturing arrow_forward
    • Publications arrow_forward
  • Patients & Families
    • Overview arrow_forward
    • Taking Part in Our Clinical Trials arrow_forward
    • Videos arrow_forward
  • Clinical Trials
    • Overview arrow_forward
    • Expanded Access Policy arrow_forward
  • Investors & Media
    • Overview arrow_forward
    • News Center arrow_forward
    • Financial Info and Governance arrow_forward
    • Stock Data arrow_forward
    • SEC Filings arrow_forward
  • Contact
  • Careers
    • Overview arrow_forward
    • US Careers arrow_forward
    • UK Careers arrow_forward

Preclinical Pipeline

Pipeline

Pipeline

  • Overview
  • Afami-cel
  • Lete-cel
  • Uza-cel

Preclinical autologous and allogeneic pipeline

Our deep preclinical pipeline includes both autologous and allogeneic therapies.

Adding to our ongoing MAGE-A4 directed autologous program, we are also focusing on the development of a T-cell therapy directed to PRAME and CD70 - both highly validated T-cell targets in solid tumors.

We have built one of the leading allogeneic T-cell platforms using human induced pluripotent stem cell lines (hIPSCs). This platform is flexible, scalable, and produces functional T-cells that kill tumor cellsĀ in vitro. We will combine this platform with everything we have learned from decades of autologous T-cell therapy research and development into a pipeline for Adaptimmune and its partners for off-the-shelf or allogeneic cell therapies. We plan to file our first allogeneic IND in 2025.

Program [Target] Trial Name(s) / Indications / Design Ind-Enabling Phase 1 Phase 2/3 Registration
afami-cel [MAGE-A4] SPEARHEAD-1 pivotal trial synovial sarcoma
Ind-Enabling complete
Phase 1 complete
Phase 2/3 complete
Registration in progress
U.S. FDA Accelerated Approval
SPEARHEAD-3 pediatric study in tumors that express MAGE-A4 (synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST), neuroblastoma or osteosarcoma)
Ind-Enabling complete
Phase 1 in progress
Phase 2/3 not started
Registration not started
lete-cel [NY-ESO] IGNYTE-ESO synovial sarcoma and MRCLS
Ind-Enabling complete
Phase 1 complete
Phase 2/3 in progress
Registration not started
uza-cel
(ADP-A2M4CD8*) [MAGE-A4]
Collaboration with Galapagos head & neck cancer and potential future solid tumor indications
Ind-Enabling in progress
Phase 1 not started
Phase 2/3 not started
Registration not started
ADP-600 [PRAME] Indications that express PRAME including synovial sarcoma, breast, NSCLC, gastroesophageal, melanoma, endometrial, ovarian and head & neck cancers. Clinical Indications TBD
Ind-Enabling in progress
Phase 1 not started
Phase 2/3 not started
Registration not started
ADP-520 [CD70] Indications that express CD70 including hematological, malignancies, acute myeloid leukemia (AML), lymphoma and renal cell carcinoma (RCC). Clinical Indications TBD
Ind-Enabling in progress
Phase 1 not started
Phase 2/3 not started
Registration not started

--The safety and efficacy of investigational products have not been established.

* Enrollment in the SURPASS family of trials with uza-cel (ADP-A2M4CD8) manufactured on the Adaptimmune manufacturing platform has been discontinued.

Publications

Review our findings and publications.

View Preclinical and Allogeneic Publications View All Publications

Latest News

We announced clinical responses across five solid tumor indications with an overall response rate of 36% and promising early durability from our next-generation SURPASS trial.

View Press Release
Adaptimmune
Disclosures Privacy Policy Disclaimer Search Sitemap Terms of Use Supply Terms Cookie Policy Manage Cookie Preferences
Linedin Twitter Youtube
© 2025 Adaptimmune. All Rights Reserved.